SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549



                                    FORM 8-K



                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


        Date of Report (date of earliest event recorded): April 25, 2001


                        InMedica Development Corporation
                        --------------------------------
               (Exact name of registrant as specified in charter)


                             Utah 0-12968 87-0397815
                             -----------------------
           (State or other juris- (Commission File No.) (IRS Employer
                  diction of incorporation) Identification No.)


                   825 N. 300 West, Salt Lake City, Utah 84103
                   -------------------------------------------
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (801) 521-9300
                                                           --------------

                                       1


5.       Other Events.
         ------------

         InMedica Development Corporation ("InMedica" or the "Company") executed
employment  contracts with its Chief Executive  Officer,  Ralph Henson,  and its
Chief  Financial  Officer,  Richard  Bruggeman,  on April 25, 2001. Mr. Henson's
contract  reaffirms  the  provisions  of  his  prior  contract  (See  8-K of the
Registrant  dated December 1, 1999) except  paragraphs one and two thereof which
are  amended  and  restated  in their  entirety  to  provide  for his full  time
employment  for the period  April 1, 2001  until  March 31,  2003.  Compensation
payable  for his  services  during  the  period is $7,000  per month  during the
remainder  of 2001 and  $8,000  per  month  for the  balance  of the term of the
contract.  Mr.  Henson is to continue as a member of the Board of  Directors  of
InMedica. Mr. Henson was also separately granted the right to earn a finders fee
of up to $15,000 for raising up to $1,000,000 for the Company.  When earned, the
fee is to be paid in restricted  common stock of the Company  valued at $.12 per
share, for a maximum of 125,000 shares.  Mr.  Bruggeman's  contract provides for
his part time  employment  as the Chief  Financial  Officer of the Company  from
April 1, 2001 until March 31, 2003. He has the option to increase the employment
to full time if warranted by the Company's  business,  at a  compensation  to be
negotiated.  Compensation under the contract is $3,500 per month beginning April
1, 2001 for the balance of the year 2001 and thereafter $4,000 per month for the
remaining term of the contract.

         The  Company has also  executed  two  promissory  notes dated April 26,
2001, payable to its Chairman, Larry E. Clark. The first note documents a series
of  existing  loans from Mr.  Clark to the  Company of  $262,250  principal  and
$26,899.23 accrued interest. The note is due in three payments as follows: on or
before May 31,  2001,  $150,000,  on or before  July 15,  2001,  $75,000 and the
balance on or before  October 15, 2001.  The second note  documents an additonal
loan from Mr. Clark to the Company of $10,000  principal and  $1,331.74  accrued
interest. The note is due in two payments as follows: on or before May 31, 2001,
$5,000 and the balance on or before July 15, 2001.  Accrued interest is included
in the notes through May 31, 2001. Thereafter interest accrues at 10% per annum.

         Effective  April 25,  2001,  the  Company  paid Mr.  Clark for  accrued
consulting  fees and accrued  interest by issuing to his family trust  1,219,025
restricted common shares of InMedica in satisfaction of $123,992 consulting fees
payable and $22,291  accrued  interest  on the fees.  The Company  also paid Mr.
Bruggeman  for accrued  consulting  fees and accrued  interest by issuing to him
464,975  restricted  common  shares  of  InMedica  in  satisfaction  of  $52,000
consulting  fees  payable  and $3,797  interest.  Shares were issued at $.12 per
share.

7(c)     Financial Statements and Exhibits.
         ---------------------------------

         (c)  Exhibits.

         The Exhibits required  to be filed as part of this  current  report  on
         Form 8-K are listed in the attached Index to Exhibits.

                                       2


                                    SIGNATURE

         Pursuant to the  requirements  of the  Securities  and  Exchange Act of
1934,  the  Registrant has duly caused this Report to be signed on its behalf by
the undersigned hereunto duly authorized.

                                    INMEDICA DEVELOPMENT CORPORATION




Dated:  May 10, 2001                By: /s/ Richard Bruggeman
- --------------------                -------------------------
                                            Richard Bruggeman, Treasurer

                                       3



                                INDEX TO EXHIBITS


Exhibit           Description

10.1              Employment Agreement, effective
                  as of April  1, 2001 between
                  the Registrant and Ralph Henson

10.2              Employment Agreement, effective
                  as of April  1, 2001 between
                  the Registrant and Richard Bruggeman




                                       4